Some new compounds, such as CLN-081 and DZD9008 also have shown auspicious activity, but platinum-based chemotherapy is still the primary first-line treatment for EGFR 20 insertion non-small cell lung cancer (10, 11). Here, EGFR is linked to non-small cell lung carcinoma.